Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Verrica Pharmaceuticals Inc VRCA

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:VRCA)

Verrica Announces Pricing of $42.0 Million Public Offering

GlobeNewswire 8 hours ago

Verrica Announces Proposed Public Offering

GlobeNewswire 23 hours ago

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

GlobeNewswire November 4, 2024

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

PR Newswire October 30, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

GlobeNewswire October 24, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Business Wire October 11, 2024

Grabar Law Office Continues to Investigate Claims on Behalf of Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA)

Newsfile October 8, 2024

Attention Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): a Securities Fraud Class Action Has Survived a Motion to Dismiss

Newsfile October 4, 2024

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

GlobeNewswire October 2, 2024

Opinion & Analysis (NDAQ:VRCA)

No current opinion is available.

Bullboard Posts (NDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) &#8211; Executing

http://beyondspx.com/2024/08/01/verrica-pharmaceuticals-inc-nasdaqvrca-executing-on-commercial-launch-of-ycanth-advancing-pipeline/
MikeTester - August 1, 2024